News

Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings, at $499 Per Month. Why GoodRx Stock Spikes.

GoodRx offers coupons for reduced prescription drug prices at retail pharmacies. The company says patients will be able to ...

GoodRx Is Soaring on a Novo Nordisk Deal. Should You Buy GDRX Stock Here?

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX ...

Stock Movers: Novo Nordisk, GoodRX, CVS

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What Investors Need to Know

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.

GoodRx (GDRX) Stock Is Sliding Tuesday: What's Going On?

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new ...

Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval

Novo said cash-paying Americans can now buy Ozempic for $499 per month through various channels including its official ...

Why Novo Nordisk Stock Popped Monday

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

GoodRx: After A 30% Surge On The Novo News, Is The Story Just Beginning?

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...